Diagnosis and non-surgical treatment of bile duct carcinoma: Developments in the past decade

Journal of Gastroenterology

Volumn 35, Issue 5, 2000, Pages 319-325

  Tamada, Kiichi ^a   Sugano, Kentaro ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Bile duct cancer; Bile duct carcinoma; Intraductal ultrasonography; Metallic stent; Molecular biology

Indexed keywords

BILE DUCT CANCER; BILE DUCT CARCINOMA; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; ECHOGRAPHY; HUMAN; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MEDICAL ASSESSMENT; MICROWAVE IRRADIATION; MOLECULAR BIOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STENT; TUMOR GROWTH;

BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CARCINOMA; CHOLANGIOGRAPHY; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; ENDOSONOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 0034130401     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350050355     Document Type: Review

References (88)

1. Tompkins R, Thomas F, Wile A, Longmire WP. Prognostic factors in bile duct carcinoma. Ann Surg 1981;194:447-57.
2. Tio TL, Cheng J, Wijers OB, Sard PR, Tytgat GN. Endosonographic TNM staging of extrahepatic bile duct cancer: comparison with pathological staging. Gastroenterology 1991;100:1351-61.
3. Sugiyama M, Atomi Y, Kubota A, Muto T. Bile duct carcinoma without jaundice: clues to early diagnosis. Hepatogastroenterology 1997;44:1477-83.
4. Tamada K, Yasuda Y, Tomiyama T, Oohashi A, Kanai N, Aizawa T, et al. Preoperative assessment of congenital bile duct dilatation using intraductal ultrasonography. Gastrointest Endosc 1999;49: 488-92.
5. Lee MG, Lee HJ, Kim MH, Kang EM, Kim YH, Lee SG, et al. Extrahepatic biliary diseases: 3D MR cholangiopancreatography compared with endoscopic retrograde cholangiopancreatography. Radiology 1997;202:663-9.
6. Magnuson TH, Bender JS, Duncan MD, Ahrendt SA, Karmon JW, Regan F. Utility of magnetic resonance cholangiography in the evaluation of biliary obstruction. J Am Coll Surg 1999;189:63-71.
7. Tamada K, Ueno N, Tomiyama T, Oohashi A, Wada S, Nishizono T, et al. Characterization of biliary strictures using intraductal ultrasonography: comparison with percutaneous cholangioscopic biopsy. Gastrointest Endosc 1998;47:341-9.
8. Ikoma A, Ueno T, Tanaka K, Saisho A, Yoshida A, Taira A. Cholesterol polyp of the common bile duct. Am J Gastroenterol 1995;90:1934-5.
9. Gilbert LA, Park YS, Ally KM. Partial biliary obstruction due to adenomyoma of the terminal common bile duct. Clin Nucl Med 1986;11:216-17.
10. Kubota Y, Takaoka M, Tani K, Ogura M, Kin H, Fujimura K. et al. Endoscopic transpapillary biopsy for diagnosis of patients with pancreaticobiliary ductal strictures. Am J Gastroenterol 1993;88:1700-4.
11. Sugiyama M, Atomi Y, Wada N, Kubota A, Muto T. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. Am J Gastroenterol 1996;91:465-7.
12. Nimura Y. Staging of biliary carcinoma: cholangiography and cholangioscopy. Endoscopy 1993;25:76-80.
13. Nimura Y, Kamiya J. Cholangioscopy. Endoscopy 1998;30:182-8.
14. Sato M, Inoue H, Ogawa S, Ohashi S, Maetani I, Igarashi Y, et al. Limitation of percutaneous transhepatic cholangioscopy for the diagnosis of the intramural extension of bile duct carcinoma. Endoscopy 1998;30:281-8.
15. Tamada K, Kurihara K, Tomiyama T, Ohashi A, Wada S, Satoh Y, et al. How many biopsies should be performed during percutaneous transhepatic cholangioscopy to diagnose biliary tract cancer. Gastrointest Endosc 1999;50:653-8.
16. Suehara N, Mizumoto K, Kusumoto M, Niiyama H, Yokahata K, Tominaga Y, et al. Telomerase activity detected in pancreatic juice 19 months before a tumor is detected in a patient with pancreatic cancer. Am J Gastroenterol 1998;93:1967-71.
17. Niiyama H, Mizumoto K, Kusumoto M, Ogawa T, Suehara N, Shimura H, et al. Activation of telomerase and its application in biopsy specimens from biliary tract neoplasms. Cancer 1999;85: 2138-43.
18. Noda T, Ido K, Ueno N, Tamada K, Ichiyama M, Tomiyama T, et al. Transpapillary intraductal ultrasonography of the bile duct without sphincterotomy. Ultrasound Int 1995;1:141-7.
19. Tamada K, Tomiyama T, Wada S, Ohashi A, Satoh Y, Miyata T, et al. Detection of bile duct cancer in an early stage by intraductal ultrasonography (in Japanese with English abstract). Endosc Deg 1999;11:1164-72.
20. Tillich M, Mischinger Hj, Preisegger KH, Rable H, Szolar DH. Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. Am J Roentgenol 1998;171:651-8.
21. Fukuda T, Iwanaga S, Sakamoto I, Aso N, Nagaoki K, Hayashi K, et al. CT of neural invasion in common bile duct carcinoma. J Comput Assist Tomogr 1998;22:351-6.
22. Hann LE, Greatrex KV, Bach AM, Fong Y, Blumgart LH. Cholangiocarcinoma at the hepatic hilus: sonographic findings. Am J Roentgenol 1997;168:985-9.
23. Tomiyama T, Ueno N, Tano S, Wada S, Miyata T, Kimura K. Assessment of right hepatic artery involvement in patients with biliary tract cancer using color Doppler ultrasonography. J Clin Ultrasound 1997;25:317-23.
24. Mukai H, Nakajima M, Yasuda K, Mizuno S, Kawai K. Evaluation of endoscopic ultrasonography in the pre-operative staging of carcinoma of the ampulla of Vater and common bile duct. Gastrointest Endosc 1992;38:676-83.
25. Sugiyama M, Hagi H, Atomi Y, Saito M. Diagnosis of portal venous invasion by pancreatobiliary carcinoma: value of endoscopic ultrasonography. Abdom Imaging 1997;22:434-8.
26. Tamada K, Ido K, Ueno N, Ichiyama M, Tomiyama T, Kimura K. Preoperative staging of extrahepatic bile duct cancer with intraductal ultrasonography. Am J Gastroenterol 1995;90:239-46.
27. Tamada K, Ido K, Ueno N, Ichiyama M, Tomiyama T, Nishizono T, et al. Assessment of portal vein invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 1995;27:573-8.
28. Tamada K, Ido K, Ueno N, Ichiyama M, Tomiyama T, Nishizono T, et al. Assessment of hepatic artery invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 1995;27:579-83.
29. Tamada K, Ido K, Ueno N, Ichiyama M, Tomiyama T, Nishizono T, et al. Assessment of the course and variations of the hepatic artery in bile duct cancer by intraductal ultrasonography. Gastrointest Endosc 1996;44:249-56.
30. Yasuda K, Mukai H, Nakajima M, Kawai K. Clinical application of ultrasonic probe in the biliary and pancreatic duct. Endoscopy 1992;24:370-5.
31. Kanemaki N, Nakazawa S, Inui K, Yoshino J, Yamao K, Okushima K. Three-dimensional intraductal ultrasonography: preliminary results of a new technique for the diagnosis of diseases of the pancreatobiliary system. Endoscopy 1997;29:726-31.
32. Tamada K, Tomiyama T, Ohashi A, Wada S, Satoh Y, Miyata T, et al. Preoperative assessment of extrahepatic bile duct carcinoma using three-dimensional intraductal US. Gastrointest Endosc 1999;50:548-54.
33. Tamada K, Ueno N, Ichiyama M, Tomiyama T, Nishizono T, Wada S, et al. Assessment of the pancreatic parenchymal invasion in bile duct cancer by intraductal ultrasonography. Endoscopy 1996;28:492-6.
34. Tamada K, Kanai N, Ueno N, Ichiyama M, Tomiyama T, Wada S, et al. Limitation of intraductal ultrasonography in differentiating between bile duct cancer in stage T1 and stage T2: in-vitro and in-vivo studies. Endoscopy 1997;29:721-5.
35. Tamada K, Kanai N, Tomiyama T, Ohashi A, Wada S, Satoh Y, et al. Prediction of the histologic type of bile duct cancer by using intraductal ultrasonography. Abdom Imaging 1999;24:484-90.
36. Itoh A, Goto H, Naitoh Y, Hirooka Y, Furukawa T, Hayakawa T. Intraductal ultrasonography in diagnosing tumor extension of cancer of the papilla of Vater. Gastrointest Endosc 1997;45:251-60.
37. Fujita N, Noda Y, Kobayasahi G, Kimura K, Yago A. Staging of bile duct carcinoma by EUS and IDUS. Endoscopy 1998;30: A132-4.
38. Engstrom CF, Wiechal KL. Endoluminal ultrasound of the bile ducts. Surg Endosc 1990;4:187-90.
39. Tamada K, Tomiyama T, Ichiyama M, Oohashi A, Wada S, Nishizono T, et al. Influence of biliary drainage catheter on bile duct wall thickness as measured by intraductal ultrasonography. Gastrointest Endosc 1998;47:28-33.
40. Tamada K, Tomiyama T, Oohashi A, Aizawa T, Nishizono T, Wada S, et al. Bile duct wall thickness measured by intraductal US in patients who have not undergone previous biliary drainage. Gastrointest Endosc 1999;49:199-203.
41. Yamaguchi K, Chijiiwa K, Saiki S, Shimizu S, Takashima M, Tanaka M. Carcinoma of the extrahepatic bile duct - mode of spread and its prognostic implications. Hepatogastroenterology 1997;44;1256-61.
42. Hayashi S, Miyazaki M, Kondo Y, Nakajima N. Invasive growth patterns of hepatic hilar ductal carcinoma. Cancer 1994;73:2922-9.
43. Tamada K, Yasuda Y, Nagai H, Tomiyama T, Tano S, Kanai N, et al. Limitation of cholangiography in assessing longitudinal spread of extrahepatic bile duct carcinoma to the hepatic side. J Gastroenterol Hepatol 1999;14:691-8.
44. Izuishi K, Tajiri H, Ryu M, Furuse J, Maru Y, Inoue K, et al. Detection of bile duct cancer by autofluorescence cholangioscopy: a pilot study. Hepatogastroenterology 1999;46:804-7.
45. Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998;187:358-64.
46. Nagino M, Nimura Y, Kamiya J, Kondo S, Uesaka K, Kin Y, et al. Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization. Hepatology 1995;21:434-9.
47. Vogl TJ, Balzar JO, Dette K, Hintze R, Pegios W, Maurer J, et al. Initially unresectable hilar cholangiocarcinoma: hepatic regeneration after transarterial embolization. Radiology 1998;208:217-22.
48. Nagai H, Ohki J, Kondo Y, Yasuda T, Kasahara K, Kanazawa K. Pancreatoduodenectomy with preservation of pylorus and gastroduodenal artery. Ann Surg 1996;223:194-8.
49. Davis PHP, Groren AK, Rauws EA, Tytgat GN, Huibregtse K. Randomized trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992; 340:1488-92.
50. Hausegger KA, Kleinert R, Lammer J, Klein GE, Flückiger F. Malignant biliary obstruction: histological findings after treatment with self-expandable stents. Radiology 1992;185:461-4.
51. Boguth L, Tatalovic S, Antonucci F, Heer M, Sulser H, Zollikober CL. Malignant biliary obstruction: clinical and histopathologic correlation after treatment with self-expanding metal prosthesis. Radiology 1994;192:669-74.
52. Mixon T, Goldschmid S, Brady PG, Boulay J. Endoscopic management of expandable metallic biliary stent occlusion. Gastrointest Endosc 1993;39:82-4.
53. Tham TCK, Carr-Locke DL, Vandervoort J, Wong RCK, Lichtenstein DR, Dam JV, et al. Management of occluded biliary Wallstents. Gut 1998;42:703-7.
54. Cremer M, Deviere J, Sugai B, Baize M. Expandable biliary metal stents for malignancies: endoscopic insertion and diathermic cleaning for tumor ingrowth. Gastrointest Endosc 1990;36:451-7.
55. Loseff SV, Druy E, Jelinger E, Fleischer D, Barth KH. Use of hottip laser probes to recanalize occluded expandable metallic biliary endoprostheses. Am J Roentgenol 1992;158:199-201.
56. Ell C, Fleig WE, Hochberger J. Broken biliary metal stent after repeated electrocoagulation for tumor ingrowth. Gastrointest Endosc 1992;38:197-9.
57. Maetani I, Inoue H, Ogawa S, Sato M, Igarashi Y. Percutaneous microwave coagulation therapy using cholangioscopy for recanalizing self-expanding metallic stents occluded by tumor ingrowth: preliminary results. Dig Endosc 1999;11:209-14.
58. Wada S, Tamada K, Tomiyama T, Ohashi A, Utsunomiya K, Higashizawa T, et al. Intraductal ultrasonographic assessment of coagulation depth during endoscopic microwave coagulation therapy in a canine model. J Gastroenterol 200;35:284-9.
59. Hyodo T, Yamanaka T. Intraductal ultrasonography in six patients with endoscopic biliary stenting. J Gastroenterol 1999;34:105-10.
60. Eschelman DJ, Shapiro MJ, Bonn J, Sullivan KL, Aldan ME, Hovsepian DM, et al. Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined-modality radiation therapy. Radiology 1996;200:717-24.
61. Born H, Neuhaus H, Rösch T, Ott R, Allescher H, Trimberger E, et al. Initial experience with a new, partially covered Wallstent for malignant biliary obstruction. Endoscopy 1996;28:699-702.
62. Hausegger KA, Thurnher S, Bodendorfer G, Zollikofer CL, Uggowitzer M, Kugler C, et al. Treatment of malignant biliary obstruction with polyurethane-covered wallstents. Am J Roentgenol 1998;170:403-8.
63. Hausegger KA, Mischinger HJ, Karaic R, Klein GE, Kugler C, Kern R, et al. Percutaneous cholangioscopy in obstructed biliary stents. Cardiovasc Intervent Radiol 1997;20:191-6.
64. Rossi P, Bezzi M, Salvatori FM, Panzetti C, Rossi M, Pavia G. Clinical experience with covered Wallstents for biliary malignancies: 23-month follow-up. Cardiovasc Intervent Radiol 1997;20: 441-7.
65. Cwikiel W. Development of an electrolytic stent: an experimental study in rats and pigs (abstract). Cardiovasc Intervent Radiol 1996;19:53.
66. Machan LS, Hunter W, Arsenault L, et al. Angiogenesis inhibition as a means for preventing stent overgrowth (abstract). Cardiovasc Intervent Radiol 1996;19:54.
67. Tamada K, Wada S, Ohashi A, et al. Intraductal US in assessing the effects of radiation therapy and prediction of patency of metallic stents in extrahepatic bile duct carcinoma. Gastrointest Endosc 2000;51 (in press).
68. Ortner MA, Liebetruth J, Schreiber S, Marco H, Ullrich W, Fusco V, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998;114:536-42.
69. Dergham ST, Dugan MC, Joshi US, Chen YC, Du W, Smith DW, et al. The clinical significance of p21 (WAF1/CIP-1) and p53 expression in pancreatic carcinoma. Cancer 1997;80:372-81.
70. Friess H, Yamanaka Y, Kobrin MS, Do DA, Buchler MW, Korc M. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995;1: 1413-20.
71. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG, Korc M, et al. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 1998;55:363-9.
72. Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998;15:344-52.
73. Freiss H, Lu Z, Andren Sandberg A, Berberat P, Zimermann A, Adler G, et al. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 1998;229:780-7.
74. Lu Z, Friess H, Graber HU, Guo X, Schilling M, Zimmermann A, et al. Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997;42:2054-63.
75. Koshiba T, Hosotani R, Wada M, Miyamoto Y, Fujimoto K, Lee JU, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998; 82:642-50.
76. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999;79:1553-63.
77. Naka T, Kobayashi M, Ashida K, Tayata N, Kaneko T, Kaibara N, et al. Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. Int J Oncol 1998;12:1111-6.
78. Sho M, Adachi M, Taki T, Hashida H, Konishi T, Huang CL, et al. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 1998;79:509-16.
79. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, et al. bax. but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998;42:414-21.
80. Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC, Nicosia SY, et al. Analysis of p53, p21WAF1, and TGF-beta 1 in human ductal adenocarcinoma of the pancreas: TGF-beta 1 protein expression predicts longer survival. Am J Clin Pathol 1998; 110:16-23.
81. Rijken AM, Offerhause GJ, Polak MM, Gouma DJ, van Gulik TM. p53 expression as a prognostic determinant in resected distal bile duct carcinoma. Eur J Surg Oncol 1999;25:297-301.
82. Rijken AM, Umezawa A, van Gulik TM, Bosnia A, Polak MM, Offorhause GJ, et al. Prognostic value of cell proliferation (Ki-67 antigen) and nuclear DNA content in clinically resectable, distal bile duct carcinoma. Ann Surg Oncol 1998;2:699-705.
83. Lee YC, Song SY, Chung JB, Kang JK, Park IS. p53 protein expression in extrahepatic bile duct cancer. Yonsei Med J 1996; 37:112-7.
84. Washington K, Gottfried MR. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver 1996;16:99-104.
85. Rijken AM, van Gulik TM, Polak MM, Sturm PD, Gouma DJ, Offerhause GJ. Diagnostic and prognostic value of incidence of K-ras codon 12 mutations in resected distal bile duct carcinoma. J Surg Oncol 1998;68:187-92.
86. Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T, Kanematsu T. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am J Gastroenterol 1991;86:1784-8.
87. Lee CS. Ras p21 protein immunoreactivity and its relationship to p53 expression and prognosis in gallbladder and extrahepatic biliary carcinoma. Eur Surg Oncol 1997;23:233-7.
88. Nishida T, Nakao K, Hamaji M, Nakahara MA, Tsujimoto M. Prognostic significance of proliferative cell nuclear antigen in carcinoma of the extrahepatic bile duct. World J Surg 1997;21:634-9.